Wikipedia -WSS

Wikipedia

author：Wikipedia 2025-10-01 21:23:54 - browse：865

The New York Stock Exchange (NYSE) — Spencer Platt/Getty Images

Biohaven Pharmaceuticals said Wednesday that a new type of experimental medicine reduced levels of a disease-causing immune molecule by up to 37% in an early-stage study of human volunteers — a result that the company called “positive” as a proof of concept but that also fell short of investor expectations.

The drug, called BHV-1300, belongs to a new class of antibody medicines that shuttle harmful proteins to the liver so they can be removed from the body. BHV-1300 is specifically designed to reduce levels of an autoantibody called IgG that is implicated in rheumatoid arthritis, myasthenia gravis, and other autoimmune disorders.

In its Phase 1 study, Biohaven tested four escalating doses of BHV-1300 in healthy volunteers, showing a reduction in levels of IgG of 5%, 15%, 30%, and 37%, respectively, the company said. The reductions in IgG levels, which occurred relatively quickly in just four to five days, did not cause significant, adverse changes in liver enzyme levels, Biohaven added — an important safety check given the mechanism of the drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Solve the antibiotic resistance crisis with preventive drugs

hotspot

WSS

Former medical device CEO who sold dummy, plastic parts convicted of fraud

Headspace, Meta partner to launch VR meditation app for Quest

STAT Readout Newsletter: Today's biggest biotech updates

Novo Nordisk obesity pill bests Wegovy in early trial

UnitedHealth quietly bought dozens of outpatient centers

Change Healthcare cyberattack prompts Medicare loan program

leisure time

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

DIEP, the 'gold standard' of breast reconstruction, is under threat

Studies point to risks of excluding people with obesity from drug trials

Psychedelics group wrestles with new pharma identity

STAT Summit: GSK CEO on pharma giant's new direction

BioMarin wins approval for gene therapy to treat hemophilia A

First medicine developed to treat MASH expected to be approved soon

Peter Hotez and the public health issue of online harassment

Precocious puberty in girls comes with mental health risks

Drug repurposing or repositioning? The language matters

The drug industry has found itself all alone in Washington

entertainment

Impact of Dobbs ruling felt at reproductive medicine meeting

Impact of Dobbs ruling felt at reproductive medicine meeting

Just how do doctors, lawmakers, and the public define abortion?

CEOs share strategies for surviving biotech slump

Change Healthcare payments predicted restored March 15

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

hotspot

leisure time

hotspot

hotspot